
Top Healthcare Dividend Stocks: Our 5 Picks for November 2026
Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.
Every article, report, and earnings note where MDT appears.

Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

MiniMed Group, Inc. Common Stock When Issued is expected to list on NASDAQ on 2026-10-01 under the symbol MMEDV. The price range has not been disclosed yet. The bull case is a global diabetes-tech platform with $3.102 billion in fiscal 2026 sales; the bear case is execution risk, heavy competition, and a float dominated by Medtronic.

Encore Medical Inc. is expected to list on the NYSE on 2026-10-01, but the price range has not been disclosed yet. The setup is straightforward: a structural heart device company with real revenue growth, but also ongoing losses and a hard regulatory path in the U.S.

Medtronic is shifting from a slow-growth story to an execution-led reacceleration, with broad-based Q1 strength across cardiovascular, neuroscience, and medical surgical. The stock earns a Buy as growth platforms like Affera, Hugo, and Micra support a fair value of $99.

Medtronic plc (MDT) rises after reporting fiscal Q4 2026 results that showed stronger revenue growth, standout cardiovascular performance, and upbeat FY27 guidance. Investors are responding to a cleaner growth narrative as the medical device giant signals improving momentum and solid cash generation.

Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.

Medtronic plc (MDT) rises after posting fiscal Q4 and full-year FY2026 results that beat guidance and showed its strongest annual revenue growth in a decade. The company also raised its dividend and issued upbeat FY2027 guidance, helping investors reprice the stock as a faster-growing medtech name.

No, Neuralink is not publicly traded. If you want exposure, the realistic paths are waiting for a future IPO, looking at comparable public medical-device stocks, or — if you're accredited — checking private secondary markets.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate MDT ReportCancel anytime